Translate page

Chronic Myeloid Leukemia: Reversing the Chronic Phase

john_goldmanDespite considerable scepticism about any possible clinical value of tyrosine kinase inhibitors (TKIs) in the early 1990s, imatinib at an oral dose of 400mg daily has now become standard initial treatment for all CML patients who present in Chronic Phase (CP). After 8 years follow up, the estimated survival for patients treated with imatinib is 85%, which is substantially better than patients treated with interferon alone or interferon plus cytarabine. The adverse effects of imatinib are definitely manageable in most instances.

Tim HughesDiagnosis and Monitoring Response in CML: New Challenge for the iCMLf

During the ASH meeting in 2009 John Goldman and I had the opportunity to meet with Pat Garcia-Gonzalez and Erin Schwartz from the Max Foundation to talk about our common interests. One of the issues that they raised was the lack of diagnostic and monitoring services for CML patients throughout many of the less developed nations.

Emerging Regions Support and Partnership (ERSAP) Preceptorship Program started

nicola_evansLaunched in December 2009 the Emerging Regions Support and Partnership (ERSAP) Preceptorship Program is a unique opportunity for clinicians from developing countries who treat Chronic Myeloid Leukemia (CML) to undertake an intensive educational program to develop and expand their CML management skills. Hematologists from Argentina, India and Madagascar now undertake the first preceptorships supported by the iCMLf.

Chronic Myeloid Leukemia - a perspective from India

hemant_malhotraDr. Hemant Malhotra is presently Professor of Medicine at the SMS Medical College Hospital & Head of the division of Medical Oncology at the Birla Cancer Center. The SMS Medical College Hospital is a 2000 bedded hospital, one of the leading teaching and patient care center in North India.